Brain bleed drug trial halted early – what we know
NCT ID NCT05953103
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called edaravone dexborneol (Sanbexin IV) in 80 people who had a brain bleed (intracerebral hemorrhage). The goal was to see if it is safe and helps recovery when added to standard care. The trial was stopped early, so the results are limited and more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBJECTS WITH CEREBRAL HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Edaravone dexborneol (Sanbexin IV)
What this could lead to
If successful, this could point toward a new treatment to improve recovery after a brain bleed.
What could go wrong
The trial was terminated early with only 80 participants, so results are limited. It is still in early testing, so safety and effectiveness are not proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.